A Randomized Non-Comparative Multicenter Phase II Study of Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Trial Profile

A Randomized Non-Comparative Multicenter Phase II Study of Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2013

At a glance

  • Drugs Everolimus (Primary) ; Sorafenib (Primary) ; Sunitinib
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2013 Actual initiation date Jul 2012 added as reported by ClinicalTrials.gov.
    • 05 Apr 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top